JCO3 Rec'd PCT/PTO rade of EPS PHILIPMENT OF COMMERCE SUBSTITUTE for PTO/SB/17(12-04)*FEE TRANSMITTAL for FY 2005 "Approved for use through 07/51/2006. OMB 0651-0032

Effective on 12/08/2004.		Сотр	olete if Known	
Ess Fees pursuant to the Conso		1. 2005 (H R. AR19)	Application Number	10/521,006
•	RANSMITTA		Filing Date	January 7, 2005
	KANSMITTA		First Named Inventor	Balkrishen Bhat
		•	Examiner Name	
			Art Unit	
TOTAL AMOUNT	OF PAYMENT	\$130	Attorney Docket Number	21135P
METHOD OF PAYME	NT (check all that apply	r)		
Deposit Account	Deposit Account Number	13-2755 Depo	osit Account Name Merck &	Co., Inc.
For the above-identif	ied deposit account, the D	Director is hereby a	uthorized to (check all that apply):
Charge fee(s)	indicated below			
Credit any ov	ernavments			
	ditional fee(s) or underpay		- 27 CER 1 16 41 17	
Charge any a	ditional fee(s) or underpay	ments of fee(s) unde	er 37 CFK 1.16 and 1.17	
FEE CALCULATION				
1. BASIC FILING, SEA	•		P	nnno.
, ,	FILING FEES	SEARCH FE		
Application Type	<u>Fee (\$)</u> 300	<u>Fee (\$)</u> 500	<u>Fee (\$)</u> 200	<u>Fees Paid (\$</u> \$0
Utility	200	100	130	
Design	200	100	130	
2. EXCESS CLAIM FI	(
Fee Description	<u> </u>	Fee (\$)		
Each claim over 20		50 200		
Each independent clair Multiple dependent cl		360		
Total Claims	Extra Claims Fe	ee (\$) Fee	Paid (\$) Multiple D	Pependent Claims
-20 =	0 x	\$50 =	3U	Fee Paid (\$)
			\$360	
Indep. Claims			Paid (\$)	
3 =	0 x	<u>\$200</u> <u> </u>	\$0	
3. APPLICATION SIZ			1 12	
				puter program listing filed in an thereof. See 35 U.S.C. 41(a)(
(G) and 37 CFR 1.16(
Total Sheets	Extra Sheets Nu	ımber of each add	litional 50 or fraction thereof	Fee (\$) Fee Paid (\$)
- 100 =	0_/50=_0	(round	up to a whole number)	0 X \$250 = \$0
4. OTHER FEE(S)				Fees Paid (\$)
Non-English Specifica	ition, \$130 fee			rees raid (3
Other: Late Oath or D	eclaration Surcharge			\$130
SUBMITTED BY			newson the case of	
Signature Signature	my Z Om	ello	Reg. Number 35,125	Telephone 732-594-4568
Name Philippe	L. Durette			Data 09/23/2005.
(Print/Type)	. Darono		I hereby certify	that this correspondence is I
			deposited with t	né United States Postal Servi I in an envelope addresse
05 ATRAN1 00000002 13	2755 10521006		Commissioner	for Patents, P.O. Box 1
517 130.GO DA			Alexandria. Viro	ginia 22313-1450, on the
			appearing below	
			,,	MERCK & CO., INC.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 26 SEP 2005

Applicants:

Balkrishen Bhat, et al.

Serial No.:

10/521,006

Case 21135P

Filed:

January 7, 2005

Examiner:

For:

NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-

DEPENDENT RNA VIRAL POLYMERASE

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Sir:

In response to the Notification of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US), mailed July 25, 2005, which is attached hereto, enclosed is a Declaration and Power of Attorney executed by the inventors.

The Notice also references that a Sequence Listing is due. This appears to have been an error.

The instant application, USSN 10/521,006 is a U.S. national phase application of PCT/US03/21589, filed July 11, 2003, which in turn claims priority to U.S. provisional application SN 60/396,252, filed July 16, 2002. The instant application, its specification and claims neither contain nor recite nucleotide or amino acid sequence disclosures.

Since the instant application does not recite or contain nucleotide or amino acid sequence disclosures, Applicants hereby request that the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosure be withdrawn, and that the requirement that a computer readable form copy of the sequence listing along with an identical written sequence listing be waived.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

y Date 9-23-2005

Serial No.: 10/521,006 Case No.: 221139P

Page No.: 2

For convenience, a copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosure is enclosed for easy reference.

Enclosed is a transmittal form authorizing payment of the \$130.00. If there are any deficiencies, please also charge these to Merck Deposit Account number 13-2755.

Respectfully submitted,

Ву

Philippe Le Durette, Reg. No. 35,125

Attorney for Applicants

Enclosure

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

September 23, 2005

Tel: (732)594-4568

 \subseteq



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.C. Dox 1450 Alexandria, Vignica 22313-1450 www.uspto.gov

OC000000016598693

ATTY. DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. 21135P Balkrishen Bhat 10/521,006 INTERNATIONAL APPLICATION NO. PCT/US03/21589 LA. FILING DATE PRIORITY DATE 000210 07/16/2002 MERCK AND CO., INC 07/11/2003 P O BOX 2000 RAHWAY, NJ 07065-0907 PHIL DURETTE **CONFIRMATION NO. 4866** 371 FORMALITIES LETTER

Date Mailed: 07/25/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 01/07/2005
- Copy of the International Search Report filed on 01/07/2005
- Preliminary Amendments filed on 01/07/2005
- Information Disclosure Statements filed on 03/31/2005
- Oath or Declaration filed on 01/07/2005
- U.S. Basic National Fees filed on 01/07/2005

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- \$130 Surcharge for providing the oath or declaration later than 30 months from the priority date (37 CFR 1.492(e)) is required.


SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

JUL & E 2002

- \$130 Late oath or declaration Surcharge.
 - This application clearly fails to comply with the requirements of 37 CFR. 1.824 4825 Applicant's attention

and 17-28-05



• A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/521 006	PCT/IS03/21580	21125D

0/521,006 PC1/US03/21589 21135I

FORM PCT/DO/EO/905 (371 Formalities Notice)